Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

706 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
Santoro A, Pilar G, Tan DSW, Zugazagoitia J, Shepherd FA, Bearz A, Barlesi F, Kim TM, Overbeck TR, Felip E, Cai C, Eddy S, McCulloch T, Schaefer ES. Santoro A, et al. Among authors: kim tm. BMC Cancer. 2024 Nov 21;24(1):1436. doi: 10.1186/s12885-024-13210-9. BMC Cancer. 2024. PMID: 39574037 Free PMC article. No abstract available.
The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Gray JE, Schenker M, Nahit Şendur MA, Leonova V, Kowalski D, Kato T, Orlova R, Chih-Hsin Yang J, Langleben A, Pilz A, Ungureanu A, Mak MP, Flavia De Angelis, Aggarwal H, Zimmer Z, Zhao B, Shamoun M, Kim TM. Gray JE, et al. Among authors: kim tm. J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02435-3. doi: 10.1016/j.jtho.2024.10.026. Online ahead of print. J Thorac Oncol. 2024. PMID: 39521434
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy.
Hochmair M, Schenker M, Dols MC, Kim TM, Ozyilkan O, Smagina M, Viktoriya L, Kato T, Fedenko A, De Angelis F, Rittmeyer A, Gray JE, Greystoke A, Aggarwal H, Huang Q, Zhao B, Lara-Guerra H, Nadal E. Hochmair M, et al. Among authors: kim tm. J Thorac Oncol. 2024 Oct 28:S1556-0864(24)02420-1. doi: 10.1016/j.jtho.2024.10.012. Online ahead of print. J Thorac Oncol. 2024. PMID: 39477187
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
Santoro A, Pilar G, Tan DSW, Zugazagoitia J, Shepherd FA, Bearz A, Barlesi F, Kim TM, Overbeck TR, Felip E, Cai C, Eddy S, McCulloch T, Schaefer ES. Santoro A, et al. Among authors: kim tm. BMC Cancer. 2024 Oct 24;24(1):1307. doi: 10.1186/s12885-024-12841-2. BMC Cancer. 2024. PMID: 39448966 Free PMC article. Clinical Trial.
706 results